Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Pacer Data & Infra Real Estate ETF (SRVR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Pacer Data & Infra Real Estate ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.08 (market cap $2.86B), while Pacer Data & Infra Real Estate ETF trades at $27.78 (market cap $300.94M). The key difference: Dyne Therapeutics Inc. Common Stock is far larger — about 9.5× Pacer Data & Infra Real Estate ETF's market cap, and Pacer Data & Infra Real Estate ETF is more actively traded (73,849 versus 3,341,579). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Pacer Data & Infra Real Estate ETF for 16 Days on average.
| DYN | SRVR | |
|---|---|---|
Market Cap | $2.86B | $300.94M |
Volume | 3,341,579 | 73,849 |
Sector | Health | Sector/Thematic |
52-Week High | $26.78 | $35.74 |
52-Week Low | $14.60 | $27.94 |
Typical Hold Time | 0 Days | 16 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
SRVR trades at $28.62, down 1.31% today, with a mixed technical outlook—bullish overall signal but bearish moving averages. Key financial ratios are unavailable, limiting fundamental assessment. Recent news highlights data center ETFs as a way to gain exposure to AI and cloud computing growth, suggesting thematic relevance.
The outlook is cautiously optimistic due to AI-driven demand for data centers, but risks include reliance on thematic trends and lack of current financial data. Investors should seek updated fundamentals to gauge valuation and growth prospects amid competitive and macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Pacer Data & Infra Real Estate ETF
Pacer Data & Infra Real Estate ETF seeks exposure to real estate companies that own digital infrastructure assets. Its holdings may include data centers, cell towers, fiber networks, and other connectivity-related real estate.
Read more on SRVR →
